对于ER-阳性HER2-阴性晚期乳腺癌的Elacestrant
Elizabeth Hageman1, Mia E Lussier1
1Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, NY, USA.
一种新的口服药物elacestrant被批准用于具有ESR1突变的晚期HR+ HER2-乳腺癌. 与标准治疗相比,它改善了先前接受过治疗的患者的无进展生存率.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 激素受体阳性 (HR+),人体表皮生长因子受体2-阴性 (HER2-) 晚期乳腺癌是一个重大的临床挑战.
- 内分泌耐药性,特别是ESR1突变,限制了治疗的有效性.
- 选择性雌激素受体降解剂 (SERDs) 是一个关键的治疗类.
研究的目的:
- 为了审查elacestrant的疗效和安全性,一个口服SERD.
- 评估elacestrant在HR+/HER2-晚期乳腺癌中的作用,特别是在ESR1突变患者中.
- 为了将elacestrant与晚期乳腺癌的绝经后患者的标准护理 (SOC) 进行比较.
主要方法:
- 在PubMed,Embase,Medline,Clinicaltrials.gov和NCCN数据库中进行文献搜索.
- 包括英语临床试验.
- 提取有关方法的数据和相关研究的结果.
主要成果:
- 在第1期和第3期试验中,elacestrant证明了无进展生存率的改善.
- 这种药物在患有ESR1突变的患者中是安全和有效的,这些患者之前的CDK 4/6抑制剂加上内分泌治疗失败了.
- 伊拉克斯特兰显示了与现有的内分泌疗法相比较的不良事件.
结论:
- 伊拉克斯特兰被FDA批准用于HR+/HER2-晚期乳腺癌,ESR1突变后进展.
- 它提供了顺序治疗的替代方案,并可能推迟化疗的使用.
- 目前正在进行的试验探索elacestrant在以前未接受治疗的患者和组合疗法中.
更多相关视频
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Mitogens and the Cell Cycle
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
